Introduction: Hyperglycaemia induces development and progression of microvascular complications in diabetes. A direct link between high glucose levels and intrarenal renin-angiotensin activation has been demonstrated. This post-hoc analysis assessed the influence of baseline glycaemic control on the reduction of albuminuria with aliskiren or placebo added to losartan in the Aliskiren in the EValuation of PrOteinuria In Diabetes (AVOID) study. Materials and methods: In AVOID, 599 patients with type 2 diabetes, hypertension and nephropathy received 6 months' aliskiren or placebo added to losartan 100 mg and optimal antihypertensive therapy. Changes in urinary albumin creatinine ratio at end of study were assessed by tertiles of baseline HbA 1c levels. Results: Patients were divided into tertiles of HbA 1c (<7.1%, 7.1 to <8.4% and ≥8.4%). There were no differences between tertiles, except patients in the highest tertile group more frequently used insulin. The antiproteinuric effect of aliskiren was consistent across tertiles, with the largest effect in the highest tertile (HbA 1c ≥8.4%). Conclusions: This post-hoc analysis of the AVOID study suggests that renin inhibition with aliskiren 300 mg once daily added to losartan 100 mg once daily plus optimal antihypertensive therapy provides reductions in urinary albumin creatinine ratio that are efficacious in all, but particularly in poorly controlled, diabetic patients.
Introduction
Blood glucose plays a central role in diabetes by defining the disease but also by causing deleterious effects in most organs and tissues over time. One such important effect is the microvascular complication nephropathy, which affects 30-40% of diabetes patients and is still the leading cause of end-stage renal disease (ESRD) worldwide. 1 Among many efforts to prevent development of nephropathy, lowering of blood glucose is important, as shown in the DCCT 2 and UKPDS 3 studies. Hyperglycaemia is recognized as an important progression promoter in relation to diabetic renal disease; however, when albuminuria develops, therapy that inhibits the renin-angiotensin-aldosterone (RAAS) system becomes paramount. The most recent treatment option with regards to RAAS blockade is direct renin inhibition, which has shown promise in initial studies in diabetes, especially in combination with other RAAS blocking compounds. [4] [5] [6] The beneficial effect of RAAS blocking treatment is evident, but has been thought to rely on reductions in circulating plasma levels of components of the RAAS, most noticeably angiotensin II. Increasing evidence is now pointing to the effect of RAAS blockers on kidney tissue (intrarenal RAAS). 7 Concomitantly, it is well recognized that elevated blood glucose also exerts local tissue damage by different enzymatic effects. 8 Elevated blood glucose leads to the formation of succinate and the recent discovery of the succinate receptor GPR91 in renal, cardiac, pulmonary and other tissues makes for an interesting connection between the local effects of elevated glucose and the intrarenal RAAS. Situated in the macula densa cells the GPR91 receptor responds to tubular succinate by releasing renin. This effect thus links excess glucose with activation of the RAAS, which is well known in diabetes. It suggests that the RAAS is increasingly activated with deterioration of glycaemic control, and that blocking RAAS at the first rate-limiting step becomes increasingly important with increasing levels of HbA 1c .
The AVOID study 6 is the first large study to investigate the effect of renin inhibition on albuminuria in patients with type 2 diabetes. In this post-hoc analysis of the study we further explore whether glycaemic control has any influence on the effect of renin inhibition.
Material and methods
The randomized, double blind, placebo-controlled AVOID study enrolled hypertensive patients between 18 and 85 years, with type 2 diabetes and nephropathy (early morning urinary albumin creatinine ratio, UACR >300 mg/g or >200 mg/g in patients receiving RAAS blockade). The methods have been described in detail in the main publication. 6 The study protocol was in accordance with the Declaration of Helsinki (2002) and was approved by local and central review boards. All patients provided written informed consent.
For the present analysis the patient population was divided according to baseline tertiles of HbA 1c . The primary endpoint was UACR reduction from baseline to end of study, secondary endpoints included change in eGFR and change in systolic and diastolic blood pressure from baseline to end of study. The impact of BMI on antiproteinuric effect was investigated. In addition, we assessed the use of antidiabetic medication in each of the three HbA 1c tertile groups.
Statistics
Baseline variables were assessed and compared between the two treatment groups according to HbA 1c tertile. For continuous variables, the p-value is from a t-test for each tertile. UACR reduction from baseline was analysed using a logistic regression model with treatment, region and subgroup as factors, with log-transformed baseline UACR as a covariate, and treatment by subgroup interaction.
Results
The baseline characteristics of the three groups can be seen in Table 1 . There were no statistically significant effects noticed in between-treatment differences in clinical or laboratory values in any of the HbA 1c tertile groups.
The effect of aliskiren treatment in terms of UACR reduction was largest in the tertile with baseline HbA 1c ≥8.4% (Figure 1 ) (tertile 1 vs. 3, p=0.052). Systolic blood pressure was reduced 0.5 mmHg by aliskiren treatment in the lowest HbA 1c tertile group, and increased with 0.6 and 1.1 mmHg in the two upper tertiles, respectively (p=0.58). During aliskiren treatments diastolic blood pressure decreased 0.7 mmHg in the lowest HbA 1c tertile, increased 1.6 mmHg in the middle tertile and decreased 0.3 mmHg in the highest tertile (p=0.35). There was no difference between HbA 1c tertile groups in terms of change from baseline in estimated glomerular filtration rate (eGFR) (data not shown). Within the tertile groups there was no significant change in HbA 1c during the duration of the study.
The BMI distribution was skewed in this study population but there was no difference in BMI between HbA 1c tertiles. Ten per cent of the patients in this analysis were morbidly obese (BMI >35 kg/m 2 ), 34% were obese (BMI Journal of the Renin-Angiotensin-Aldosterone System 13 (2) >30 kg/m 2 ), 49% were overweight (BMI ranging from 25 to 30 kg/m 2 ) and 7% were normal. There was no interaction of BMI on the effect of renin inhibition.
When assessing the use of antidiabetic medication in the aliskiren treated group we found that insulin use (defined as percentage of patients using insulin at any time during randomized treatment, regardless of insulin type or dose) was more frequent in patients with higher baseline HbA 1c (Table 2 ). There were no differences in use of oral antidiabetic drugs.
Discussion
From this post-hoc analysis of the AVOID study we have indications that renin inhibition with aliskiren 300 mg once daily on top of standard renoprotective treatment has the most pronounced antialbuminuric effect in the category of patients that need it the most, namely the patients with poorest glycaemic control, prone to progression of diabetic kidney disease. Although improved glycaemic control is known to protect against progression of nephropathy, the clinical reality is that many diabetic patients remain in less than optimal glycaemic control and thus may need renoprotective therapy from multiple drug classes.
In a recent a publication from the RASS study 9 it was concluded that RAAS blockade is effective in preventing the microvascular complication diabetic retinopathy in patients with type 1 diabetes with a baseline HbA 1c above 7.5%. This could be another indication of the influence of glycaemic control on the efficacy of RAAS blockade.
BMI has recently been shown to be an important determinant for renal events in the REIN study, 10 which is investigating the effect of ramipril on progression of non-diabetic nephropathy. Even more important was the finding that the protective effect of ramipril was more pronounced in obese patients, even after adjustment from confounding factors. In our study in patients with type 2 diabetes and albuminuria, the BMI distribution was quite different from the REIN population, as obese patients were much more frequent in our population (mean BMI 32.1 [range 18-57] kg/m 2 ).
If renin release in the intra-renal compartment is augmented during hyperglycaemia through the effect of the GPR91 receptor, renin inhibition could theoretically have improved efficacy in that situation.
The AVOID study was not designed to intervene in or intensify antiglycaemic treatment. It is probable that improved glycaemic control can improve renal prognosis, as seen in the ADVANCE study, 11 but with a treatment duration of only 24 weeks in the AVOID study, it is less likely that strict glycaemic control would have renoprotective effects.
To our knowledge, this is the first time the effect of renin inhibition has been analysed in relation to level of glycaemic control, but as this is a post-hoc analysis, the results can only be hypothesis-generating, and need confirmation in prospective studies. When ALTITUDE, the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints study, 12 is concluded, more evidence will be available to confirm or reject these findings.
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